RPH-051

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameRPH-051
Drug Alias NameRPH-051
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsUpdating
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesR-Pharm Jsc
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm Jsc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A